类胰蛋白酶抑制剂对人大肠肥大细胞组胺释放的影响

目的 :研究类胰蛋白酶抑制剂 (TPI)对人大肠肥大细胞释放组胺的影响。方法 :大肠组织经胶原酶和透明质酸酶消化后 ,将细胞成分用全HBSS重新悬浮。肥大细胞在LP4试管中于37℃条件下与各种刺激剂反应 15min而完成激发过程。激发液中的组胺水平用以玻璃纤维为基础的荧光方法测定。结果 :4种TPI中 ,高浓度的亮抑酶肽素和鱼精蛋白可刺激人大肠肥大细胞释放组胺 ;而TLCK和乳铁蛋白则无明显的刺激作用。 4种TPI均可以剂量依赖的方式抑制抗IgE抗体诱导的大肠肥大细胞释放组胺。最大浓度的亮抑酶肽素(2 0 0mmol/L)、TLCK(10 0mmol/L)、乳铁蛋白 (30mmol/L)和鱼精蛋白 (10 0mg/L) ,可分别抑制 4 8.7%、36 .7%、4 0 .2 %和 34.1%的组胺释放。在 37℃条件下 ,将 4种TPI同大肠肥大细胞预培养 2 0min ,与未进行预培养相比较 ,它们对抗IgE抗体诱导的组胺释放无明显改变。 4种TPI还可抑制CI诱导的组胺释放 ,抑制范围在 2 5 %～ 32 %之间。与抗IgE抗体诱导的组胺释放则不同 ,与大肠肥大细胞预培养 2 0min ,与未进行预培养相比较 ,亮抑酶肽素和TLCK对CI诱导的组胺释放的抑制作用明显增强 ;而鱼精蛋白则无此作用。结论 :我们首次发现TPI可抑制人大肠肥大细胞IgE抗体依赖和非IgE抗体依赖的组胺释放 ,提示TPI可望成为炎症性肠

Effect of tryptase inhibitors on histamine release from human colon mast cells

AIM: To investigate the effect of tryptase inhibitors (TPIs) on histamine release from human colon mast cells. METHODS: Human mast cells were prepared by digestion of colon tissue and with collagenase and hyaluronidase, cultured with four kinds of TPIs, leupeptin, protamine, TLCK, and lactoferrin for 15 min at 37 degrees Celsius respectively. A glass fibre-based fluorometry assay was used to detect histamine in mast cell suspension. RESULTS: 200 mmol/L leupeptin and 100 mmol/L protamine were able to stimulate histamine release from colon mast cells, while TLCK and lactoferrin did not. All TPIs inhibited anti-IgE-induced histamine release in a concentration dependent manner, and the inhibitory rates were 48.7%, 36.7%, 40.2% and 34.1%, respectively. However preincubation of TPIs with mast cells for 20 min at 37 degrees Celsius before adding anti-IgE had little effect on anti-IgE induced histamine release. All TPIs were able to inhibit calcium ionophore (CI)-induced histamine release, and the maximum inhibition rate was between 25%-32%. Inhibition on histamine release by leupeptin and TLCK obviously enhanced when colon mast cells were preincubated with them for 20 min before adding CI. However, under the same condition, protamine failed to inhibit histamine release. CONCLUSION: We prove for the first time that TPIs inhibit anti-IgE-and CI-induced histamine release from human colon mast cells, suggesting that it is possible to treat inflammatory bowel disease or other mast cell-related diseases by using TPIs.